Wei, Huiqiang published the artcileNovel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury, Quality Control of 73874-95-0, the main research area is hydroxypyrazolyl pyrimidinecarbonylamine preparation PHD2 HDAC inhibitor acute kidney injury; Acute kidney injury; HDACs; Hybrid inhibitor; PHD2; Renal protecting.
Acute kidney injury (AKI) is associated with high morbidity and mortality. Cisplatin is a common chemotherapeutic, but its nephrotoxicity-driven AKI limits its clin. application. Currently, there are no specific and satisfactory therapies in the clinic for AKI. Inhibitors of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PHD2) or histone deacetylase (HDACs) had shown renoprotective effects against AKI in preclin. studies. This study aimed to develop a novel therapeutic to prevent AKI progression by targeting PHD2 and HDACs simultaneously. We designed and synthesized a series of PHD2/HDACs hybrid inhibitors. The initial drug activity screening identified a candidate compound 2-{4-[(4-Hydroxy-2-pyrazol-1-yl-pyrimidine-5-carbonyl)amino]-piperidin-1-yl}-N-hydroxy-pyrimidine-5-carboxylamide, which exhibited potent inhibitory activities against PHD2 and HDAC1/2/6. Cellular analyses further showed that 2-{4-[(4-Hydroxy-2-pyrazol-1-yl-pyrimidine-5-carbonyl)amino]-piperidin-1-yl}-N-hydroxy-pyrimidine-5-carboxylamide did not affect cisplatin′s antitumor activity in cancer cells but strongly protected cisplatin-induced toxicity on HK-2 cells. In vivo studies with the cisplatin-induced AKI mouse model demonstrated that 31c remarkably alleviated kidney dysfunction with suppressed plasma BUN/SCr and increased EPO levels. The potent renoprotective effects of 2-{4-[(4-Hydroxy-2-pyrazol-1-yl-pyrimidine-5-carbonyl)amino]-piperidin-1-yl}-N-hydroxy-pyrimidine-5-carboxylamide on AKI were confirmed by significant improvements in pathol. kidney conditions in the mouse model. These results suggest that the novel PHD2/HDACs hybrid inhibitor, 2-{4-[(4-Hydroxy-2-pyrazol-1-yl-pyrimidine-5-carbonyl)amino]-piperidin-1-yl}-N-hydroxy-pyrimidine-5-carboxylamide, has a clin. potential as the renoprotective agent for the treatment/prevention of cisplatin-induced AKI for various cancers.
European Journal of Medicinal Chemistry published new progress about Acute kidney injury. 73874-95-0 belongs to class piperidines, name is tert-Butyl piperidin-4-ylcarbamate, and the molecular formula is C10H20N2O2, Quality Control of 73874-95-0.
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem